| Publications |
Download Publication
Contacting PharmaNeuroBoost
For more information on PharmaNeuroBoost and its innovative
product portfolio please contact:
Elly Daniëls, PA
PharmaNeuroBoost NV
Alkerstraat 30 A
3570 Alken, Belgium
Tel.: +32 11 480 750
Fax: +32 11 484 923
E-mail: info@pharmaneuroboost.com
- ECNP 2011 Interaction - Interaction of Pipamperone,
Citalopram, and Genetic Variables in the Prediction of
Antidepressant Response - ECNP 2011 Phase_III_Dose_Selection - Phase III Dose
Selection for PNB01, a Novel Fixed-Dose Combination
Antidepressant Inducing a Faster and Sustained Response - NCDEU 2011 ESR - Creating a New, Clinically Relevant
Endpoint in the PIPCIT Trial Program: The ESR (Early and
Sustained Antidepressant Response) - NCDEU 2011 PNB01 Pipeline - The PNB01 Clinical
Development Program: A Novel Boosting Antidepressant
Therapy - ACNP 2010 - Interaction of Pipamperone Augmentation of
Citalopram and Genetic Variables in the Prediction of
Antidepressant Response - Bionity.com News - PharmaNeuroBoost's lead product in
major depression receives IND approval from FDA - EPA 2010 - Addition of a Selective 5-HT2A/D4 Antagonist
Accelerates the Antidepressant Effects of Citalopram - NCDEU 2010 - How to Assess the Speed of
Antidepressant Effect: Insights From the PIPCIT Clinical
Trial Program - SOBP 2010 - Selective Serotonergic Properties of Low-
Dose Pipamperone May Enhance Antidepressant Effect:
Preclinical Evidence - ECNP 2010 - Low dose Pipamperone significantly binds 5-
HT2A receptor without clinically relevant D2 receptor
binding: a PET study - Psychological Medicine - Citalopram plus low-dose
pipamperone versus citalopram plus placebo in patients
with major depressive disorder: an 8-week, double-blind,
randomized study on magnitude and timing of clinical
response. - A.G. Wade, G. M. Crawford, C. B. Nemeroff, A.
F. Schatzberg, T. Schlaepfer, A. McConnachie, L. Haazen
and E. Buntinx - Psychological Medicine, Available on CJO
2010 doi:10.1017/S0033291711000158
Contacting PharmaNeuroBoost
For more information on PharmaNeuroBoost and its innovative
product portfolio please contact:
Elly Daniëls, PA
PharmaNeuroBoost NV
Alkerstraat 30 A
3570 Alken, Belgium
Tel.: +32 11 480 750
Fax: +32 11 484 923
E-mail: info@pharmaneuroboost.com
| © PharmaNeuroBoost 2012 - All Rights Reserved |
 |  |  |  |  |  |  |  |  |
| News Highlights |
April 2nd, 2012
PharmaNeuroBoost
invited to present the
novel pharmacological
concept of its clinical
stage antipsychotic
PNB02 at the high
level CNS meeting
NCDEU in Phoenix,
USA, on May 29th
2012.
September 30th, 2011
First Patients Enrolled
in the PNB01 Phase III
clinical develop- ment
program in Major
Depression
PharmaNeuroBoost
invited to present the
novel pharmacological
concept of its clinical
stage antipsychotic
PNB02 at the high
level CNS meeting
NCDEU in Phoenix,
USA, on May 29th
2012.
September 30th, 2011
First Patients Enrolled
in the PNB01 Phase III
clinical develop- ment
program in Major
Depression